Daniel Lynch, Director at Blueprint Medicines Corp (BPMC), sold 35,000 shares at $75.15 ($2.6M) on 2018-02-12, disclosed to the SEC on 2018-02-14.
Open-market sale of $2.6M BPMC by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $73.27 | 3,996 | $293K | 11.2% |
| 2 | $73.27 | 3,996 | $293K | 11.2% |
| 3 | $74.31 | 3,748 | $279K | 10.6% |
| 4 | $74.31 | 3,748 | $279K | 10.6% |
| 5 | $75.15 | 5,636 | $424K | 16.2% |
| 6 | $75.15 | 5,636 |
| $424K |
| 16.2% |
| 7 | $75.96 | 2,590 | $197K | 7.5% |
| 8 | $75.96 | 2,590 | $197K | 7.5% |
| 9 | $77.18 | 1,530 | $118K | 4.5% |
| 10 | $77.18 | 1,530 | $118K | 4.5% |
| Total | $74.84 avg | 35,000 | $2.6M | 100% |
| Filing → |
| SWTX | SELL | 2025-02-12 | $15.4M | — | Filing → |
| BPMC | SELL | 2018-02-16 | $1.0M | — | Filing → |
| BPMC | SELL | 2017-11-17 | $420K | — | Filing → |